Abstract
Among various vaccine candidates, subunit vaccines play an important role in immune protection against tuberculosis (TB). Calcium phosphate (CP) is considered as a strong inorganic adjuvant due to its great potential in increasing immune responses. The purpose of this study was to evaluate specific immune responses following the administration of trifusion-CP nanoparticles. The physiochemical properties of these nanoparticles, including morphology, particle size, zeta potential and adsorption rate, were measured in vitro. Subcutaneous immunization was performed three times on days 0, 14, and 28. Two weeks after the last administration, IFN-gamma, IL-4, and TGF-beta levels were measured by indirect enzyme linked immunosorbent assay (ELISA). The trifusion protein was successfully adsorbed onto calcium phosphate nanoparticles. The mean sizes of the resultant trifusion- CPN and CPN were 97.84 ± 12.08 and 67 ± 11.85 nm, respectively. CPN containing trifusion had stronger ability to induce IFN-gamma than the control groups. IL-4 and TGF-beta secretions in trifusion and trifusion-CPN groups were higher than those in the PBS group. However, there was no significant (p > 0.05) difference in IL-4 and TGFbeta concentrations between trifusion group and trifusion- CPN group. Therefore, calcium phosphate nanoparticles are good candidates for immunization against TB because antigen can be easily adsorbed onto CPN and strong cellular immune responses against CPN-antigen can be stimulated.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Chan, J., S. Mehta, S. Bharrhan, Y. Chen, J. M. Achkar, A. Casadevall, and J. Flynn (2014) The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin. Immunol. 26: 588–600.
Gagneux, S. (2012) Host–pathogen coevolution in human tuberculosis. Philos. Trans. R. Soc. B: Biol. Sci. 367: 850–859.
Nelson, L., E. Talbot, M. Mwasekaga, P. Ngirubiu, R. Mwansa, M. Notha, and C. Wells (2005) Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 366: 488–490.
Ryan, N. J. and J. H. Lo (2014) Delamanid: First global approval. Drugs 74: 1041–1045.
Cohen, J. (2013) Approval of novel TB drug celebrated-with restraint. Science 339: 130-130.
Aronson, N. E., M. Santosham, G. W. Comstock, R. S. Howard, L. H. Moulton, E. R. Rhoades, and L. H. Harrison (2004) Longterm efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 291: 2086–2091.
Andersen, P. and T. M. Doherty (2005) The success and failure of BCG—implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3: 656–662.
Rook, G. A., K. Dheda, and A. Zumla (2005) Immune responses to tuberculosis in developing countries: Implications for new vaccines. Nat. Rev. Immunol. 5: 661–667.
Ahsan, M. J. (2015) Recent advances in the development of vaccines for tuberculosis. Therapeutic Adv. Vaccines 3: 66–75.
Montagnani, C., E. Chiappini, L. Galli, and M. de Martino (2014) Vaccine against tuberculosis: What’s new? BMC Infectious Diseases 14: S2.
Knudsen, N. P. H., S. Nørskov-Lauritsen, G. M. Dolganov, G. K. Schoolnik, T. Lindenstrøm, P. Andersen, E. M. Agger, and C. Aagaard (2014) Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc. Natl. Acad. Sci. 111: 1096–1101.
Amini, Y., M. tebianian, N. Mosavari, M. fasihi ramandi, S. M. Ebrahimi, H. Najminejad, M. Dabaghian, and M. Abdollahpour (2016) Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen. Artif. Cell. Nanomed. Biotechnol. 28: 1–6.
Mahmood, A., S. Srivastava, S. Tripathi, M. A. Ansari, M. Owais, and A. Arora (2011) Molecular characterization of secretory proteins Rv3619c and Rv3620c from Mycobacterium tuberculosis H37Rv. FEBS J. 278: 341–353.
Bonanni, D., L. Rindi, N. Lari, and C. Garzelli (2005) Immunogenicity of mycobacterial PPE44 (Rv2770c) in Mycobacterium bovis BCG-infected mice. J. Med. Microbiol. 54: 443–448.
Romano, M., L. Rindi, H. Korf, D. Bonanni, P. -Y. Adnet, F. Jurion, C. Garzelli, and K. Huygen (2008) Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine 26: 6053–6063.
Lin, P. L., J. Dietrich, E. Tan, R. M. Abalos, J. Burgos, C. Bigbee, M. Bigbee, L. Milk, H. P. Gideon, and M. Rodgers (2012) The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 122:303.
Hu, Y., F. Movahedzadeh, N. G. Stoker, and A. R. Coates (2006) Deletion of the Mycobacterium tuberculosis α-crystallin-like hspX gene causes increased bacterial growth in vivo. Infect. Immun. 74: 861–868.
Niu, H., J. Peng, C. Bai, X. Liu, L. Hu, Y. Luo, B. Wang, Y. Zhang, J. Chen, and H. Yu (2015) Multi-stage tuberculosis subunit vaccine candidate LT69 provides high protection against Mycobacterium tuberculosis infection in mice. PLoS One 10: e0130641.
Yuan, X., X. Teng, Y. Jing, J. Ma, M. Tian, Q. Yu, L. Zhou, R. Wang, W. Wang, and L. Li (2015) A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection. Appl. Microbiol. Biotechnol. 99: 10587–10595.
Mustafa, A. S. (2002) Development of new vaccines and diagnostic reagents against tuberculosis. Mol. Immunol. 39: 113–119.
Seenuvasan, M., C. G. Malar, S. Preethi, N. Balaji, J. Iyyappan, M. A. Kumar, and K. S. Kumar (2013) Fabrication, characterization and application of pectin degrading Fe3O4-SiO2 nanobiocatalyst. Mat. Sci. Eng. C 33: 2273–2279.
Tafaghodi, M. and S. Rastegar (2010) Preparation and in vivo study of dry powder microspheres for nasal immunization. J. Drug Target. 18: 235–242.
Tafaghodi, M., A. Khamesipour, and M. Jaafari (2010) Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental Autoclaved Leishmania major (ALM) and Quillajasaponins. Tropical Biomed. 27: 639–650.
Zelphati, O., C. Nguyen, M. Ferrari, J. Felgner, Y. Tsai, and P. Felgner (1998) Stable and monodisperse lipoplex formulations for gene delivery. Gene Therapy 5: 1272–1282.
Epple, M. and A. Kovtun (2010) Functionalized calcium phosphate nanoparticles for biomedical application. Key Eng. Mat. 441: 299–305.
Seenuvasan, M., K. S. Kumar, M. Kumar, J. Iyyappan, and J. R. G. Suganthi (2014) Response surface estimation and canonical quantification for the pectin degrading Fe3O4-SiO2 nanobiocatalyst fabrication. Internat. J. ChemTech. Res. 6: 3618–3627.
Koppad, S., G. D. Raj, V. Gopinath, J. J. Kirubaharan, A. Thangavelu, and V. Thiagarajan (2011) Calcium phosphate coupled Newcastle disease vaccine elicits humoral and cell mediated immune responses in chickens. Res. Veterinary Sci. 91: 384–390.
He, Q., A. Mitchell, T. Morcol, and S. J. Bell (2002) Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clinic. Diagnostic Lab. Immunol. 9: 1021–1024.
He, Q., A. R. Mitchell, S. L. Johnson, C. Wagner-Bartak, T. Morcol, and S. J. Bell (2000) Calcium phosphate nanoparticle adjuvant. Clinic. Diagnostic Lab. Immunol. 7: 899–903.
Behera, T. and P. Swain (2011) Antigen adsorbed calcium phosphate nanoparticles stimulate both innate and adaptive immune response in fish, Labeo rohita H. Cell. Immunol. 271: 350–359.
Brandt, L., M. Elhay, I. Rosenkrands, E. B. Lindblad, and P. Andersen (2000) ESAT-6 Subunit Vaccination against Mycobacterium tuberculosis. Infect. Immun. 68: 791–795.
Lindblad, E. B. (2004) Aluminium adjuvants-in retrospect and prospect. Vaccine 22: 3658–3668.
Knuschke, T., V. Sokolova, O. Rotan, M. Wadwa, M. Tenbusch, W. Hansen, P. Staeheli, M. Epple, J. Buer, and A. M. Westendorf (2013) Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J. Immunol. 190: 6221–6229.
Singh, M., M. Ugozzoli, J. Kazzaz, J. Chesko, E. Soenawan, D. Mannucci, F. Titta, M. Contorni, G. Volpini, and G. Del Guidice (2006) A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24: 1680–1686.
Relyveld, E. and J. Chermann (1994) Humoral response in rabbits immunized with calcium phosphate adjuvanted HIV-1 gp160 antigen. Biomed. Pharmacotherapy 48: 79–83.
Jones, S., C. Asokanathan, D. Kmiec, J. Irvine, R. Fleck, D. Xing, B. Moore, R. Parton, and J. Coote (2014) Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity. Vaccine 32: 4234–4242.
Berridge, M. J., P. Lipp, and M. D. Bootman (2000) The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1: 11–21.
Marongiu, L., M. Donini, L. Toffali, E. Zenaro, and S. Dusi (2013) ESAT-6 and HspX improve the effectiveness of BCG to induce human dendritic cells-dependent Th1 and NK cells activation. PLoS One 8: e75684.
Hanif, S., R. Al-Attiyah, and A. Mustafa (2010) Molecular cloning, expression, purification and immunological characterization of three low-molecular weight proteins encoded by genes in genomic regions of difference of mycobacterium Tuberculosis. Scand. J. Immunol. 71: 353–361.
Manolova, V., A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M. F. Bachmann (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38: 1404–1413.
Xiang, S. D., A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P. L. Mottram, and M. Plebanski (2006) Pathogen recognition and development of particulate vaccines: Does size matter? Method. 40: 1–9.
Cuccu, B., G. Freer, A. Genovesi, C. Garzelli, and L. Rindi (2011) Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44. BMC Microbiol. 11:167.
Pitt, J. M., S. Blankley, H. McShane, and A. O’Garra (2013) Vaccination against tuberculosis: How can we better BCG? Microbial. Pathogen. 58: 2–16.
Sokolova, V., T. Knuschke, A. Kovtun, J. Buer, M. Epple, and A. M. Westendorf (2010) The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomat. 31: 5627–5633.
Costello, A.D.L., A. Kumar, V. Narayan, M. Akbar, S. Ahmed, C. Abou-Zeid, G. Rook, J. Stanford, and C. Moreno (1992) Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans. Royal Soc. Tropical Med. Hygiene 86: 686–692.
Achkar, J. M., J. Chan, and A. Casadevall (2015) B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunolog. Rev. 264: 167–181.
Torrado, E., J. J. Fountain, R. T. Robinson, C. A. Martino, J. E. Pearl, J. Rangel-Moreno, M. Tighe, R. Dunn, and A. M. Cooper (2013) Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse. PLoS One 8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amini, Y., Moradi, B., Tafaghodi, M. et al. TB trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice. Biotechnol Bioproc E 21, 653–658 (2016). https://doi.org/10.1007/s12257-016-0326-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12257-016-0326-y